Table 2.
Summary of the applications of MSCs in AR model.
| Animals | Source of MSCs | Administration and dosage | Effect | Reference |
|---|---|---|---|---|
| BALB/c mice | BALB/c mice adipose tissue | Tail vein injection, 2 × 106, once a day for 3 days | Y | [35] |
| Albino rats | Albino rats adipose tissue | Intraperitoneal injection, 1 × 106, weekly for 3 weeks | Y | [36] |
| BALB/c mice | Human tonsil tissue | Intravenous injection, 0.5 × 106, once a day for 6 days | Y | [37] |
| Mice | Mice nasal mucosa | Tail vein injection, once a day for 3 days | Y | [38] |
| BALB/c mice | BALB/c mice bone marrow | Intravenous injection, 0.5 × 106, once a day for 2 weeks | Y | [39] |
| BALB/c mice | BALB/c mice bone marrow | Intraperitoneal injection, 1 × 106/2 × 106, 1 dose | Y | [40] |
| Sprague-Dawley rats | Human umbilical cord | Intraperitoneal injection, 5 × 106/2 × 106, 1 dose before/after AR rat model construction or weekly for 4 weeks after AR rat model construction | Y | [41] |
Abbreviations: Y: effect was shown.